AI assistant
Onxeo — Share Issue/Capital Change 2015
Sep 3, 2015
1573_dva_2015-09-03_cc0bbecb-5979-4ff9-bb56-9114233962d9.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Disclosure of total number of voting rights and number of shares in the capital at August 31, 2015
Paris, September 3, 2015 – Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority):
| Date | Total number of outstanding shares |
Total number of voting rights |
|---|---|---|
| August 31, 2015 | 40, 552, 083 | Theoretical number of voting rights: 40, 552, 083 (including treasury shares) Number of real voting rights: 40, 510, 182 (without treasury shares) |
At August 31, 2015, the Company's capital stands at €10,138,020.75.
About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, through developing innovative therapeutic alternatives to "make the difference". The Onxeo teams are determined to develop innovative medicines to provide patients with hope and significantly improve their lives.
Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma Validive® (Clonidine Lauriad® ): Positive complete results of the Phase II trial in severe oral mucositis Beleodaq® (belinostat): registered in the US in 2 nd line treatment of peripheral T-cell lymphoma For more information, visit the website www.onxeo.com
Contacts : Judith Greciet, CEO [email protected] Nicolas Fellmann, CFO [email protected] +33 1 45 58 76 00
Caroline Carmagnol and Florence Portejoie [email protected] +33 6 64 18 99 59 / +33 1 44 54 36 66